Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Maxcyte Inc's Business Segments
Maxcyte Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Description of Maxcyte Inc
MaxCyte Inc. is a leading global provider of cell-engineering technology and an innovator in driving the development of advanced, high-performance cell-based medicines. The company is headquartered in Gaithersburg, Maryland, United States.
MaxCyte's core technology, known as Flow Electroporation, enables the rapid and efficient modification of cells for a wide range of applications in life sciences research, therapeutic development, and biomanufacturing. This proprietary cell-engineering platform has the potential to revolutionize the way therapies are developed and delivered, offering significant advantages over traditional methods.
The Flow Electroporation technology harnesses the power of electricity to deliver molecules into living cells, such as nucleic acids, proteins, and small molecules. This process can be applied to a wide variety of cell types, including primary cells, stem cells, immune cells, and cell lines. MaxCyte's technology delivers superior transfection efficiency and cell viability, ensuring reproducible results and high-quality engineered cells for various applications.
One of the key areas where MaxCyte's technology has shown great potential is in the field of cell-based therapies. It has been successfully used to modify immune cells, such as T-cells, for the development of next-generation cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies. By precisely engineering these immune cells, MaxCyte aims to enhance their anti-tumor activity and improve patient outcomes.
MaxCyte also offers its Flow Electroporation technology for use in research applications, allowing scientists to perform drug discovery, gene function studies, and protein production with greater precision and efficiency. The technology has been adopted by numerous academic institutions and pharmaceutical companies worldwide, helping to accelerate scientific discoveries and the development of new therapeutic candidates.
In addition to its cell-engineering platform, MaxCyte provides its customers with comprehensive support, including expert training, technical assistance, and protocol optimization. The company also offers a range of consumables and reagents specifically designed for use with its Flow Electroporation technology, ensuring seamless integration and optimal performance.
MaxCyte holds a strong intellectual property portfolio, with numerous patents and patent applications covering its cell-engineering technology and related applications. This intellectual property gives the company a competitive edge in the rapidly evolving field of cell-based therapies and positions it as a leader in the industry.
Overall, MaxCyte Inc. is at the forefront of cell-engineering technology, driving innovation and advancing the development of advanced cell-based medicines. With its proprietary Flow Electroporation platform, the company is enabling scientists and researchers to push the boundaries of what is possible in therapeutic development and biomanufacturing.
MaxCyte's core technology, known as Flow Electroporation, enables the rapid and efficient modification of cells for a wide range of applications in life sciences research, therapeutic development, and biomanufacturing. This proprietary cell-engineering platform has the potential to revolutionize the way therapies are developed and delivered, offering significant advantages over traditional methods.
The Flow Electroporation technology harnesses the power of electricity to deliver molecules into living cells, such as nucleic acids, proteins, and small molecules. This process can be applied to a wide variety of cell types, including primary cells, stem cells, immune cells, and cell lines. MaxCyte's technology delivers superior transfection efficiency and cell viability, ensuring reproducible results and high-quality engineered cells for various applications.
One of the key areas where MaxCyte's technology has shown great potential is in the field of cell-based therapies. It has been successfully used to modify immune cells, such as T-cells, for the development of next-generation cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies. By precisely engineering these immune cells, MaxCyte aims to enhance their anti-tumor activity and improve patient outcomes.
MaxCyte also offers its Flow Electroporation technology for use in research applications, allowing scientists to perform drug discovery, gene function studies, and protein production with greater precision and efficiency. The technology has been adopted by numerous academic institutions and pharmaceutical companies worldwide, helping to accelerate scientific discoveries and the development of new therapeutic candidates.
In addition to its cell-engineering platform, MaxCyte provides its customers with comprehensive support, including expert training, technical assistance, and protocol optimization. The company also offers a range of consumables and reagents specifically designed for use with its Flow Electroporation technology, ensuring seamless integration and optimal performance.
MaxCyte holds a strong intellectual property portfolio, with numerous patents and patent applications covering its cell-engineering technology and related applications. This intellectual property gives the company a competitive edge in the rapidly evolving field of cell-based therapies and positions it as a leader in the industry.
Overall, MaxCyte Inc. is at the forefront of cell-engineering technology, driving innovation and advancing the development of advanced cell-based medicines. With its proprietary Flow Electroporation platform, the company is enabling scientists and researchers to push the boundaries of what is possible in therapeutic development and biomanufacturing.
Reportable Segments
1
Largest Segment
Cell Engineering Technology Segment
Total Revenue
$ 10
Countrys Reported
1
Revenue Share by Reportable Segment - Q1 FY2026
- Cell Engineering Technology Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Cell Engineering Technology Segment | $ 10 | 100% |
Revenue Share by Country - Q1 FY2026
- US68.6%
Revenue by Geographic Country - Q1 FY2026
| Country | Revenue (Millions) | % of Total |
|---|---|---|
| US | $ 7 | 68.6% |
Revenue by Product & Service Category - Q1 FY2026
- License57.3%
- Product37.7%
- Assay and other service revenue5%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 6 | 57.3% |
| Product | $ 4 | 37.7% |
| Assay and other service revenue | $ 0 | 5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Annual (fiscal-year) segment data is not yet available for Maxcyte Inc. Quarterly results are shown above.
Maxcyte Inc's Business Overview
MaxCyte Inc. is a biotechnology company specializing in the advancement of cell-based therapies and drug development through its unique cell engineering technology. The company offers a range of products and services aimed at empowering researchers and developers in the fields of cell therapy, gene therapy, and biomanufacturing. Below is a comprehensive overview of MaxCytes segments, products, and services.
Segments
1. Cell Therapy:
- MaxCyte is actively involved in the cell therapy space, focusing on providing tools that enable the engineering of cells for therapeutic purposes. This includes applications for cancer treatments and regenerative medicine.
2. Gene Therapy:
- The company develops technology that supports the delivery of genetic material into cells. This is pivotal for the development of gene therapies aimed at addressing genetic disorders and diseases.
3. Biomanufacturing:
- MaxCyte provides solutions for the scalable production of cells and biologics, making it an essential partner for companies engaged in the manufacturing of cell-based products.
Products
1. MaxCyte® GT Devices:
- These are scalable, automated systems designed for the transfection (delivery of nucleic acids into cells) of a wide variety of cell types, including stem cells and primary cells. They are instrumental in research and product development stages.
2. Large-Scale Transfection Systems:
- MaxCyte offers advanced transfection systems capable of handling significant volumes, making them suitable for commercial production of cell therapies and vaccines.
3. MaxCyte® ExPERT™ System:
- A key product for high-performance transfection, the ExPERT system is utilized for various applications, including CRISPR gene editing, antibody production, and CAR-T cell therapies.
4. Cell Line Development:
- The company provides tools and protocols for developing stable cell lines that are essential for producing biologics, offering a customization service according to client needs.
5. Product Automation Solutions:
- MaxCyte integrates automation into its offerings, enabling high-throughput processing and increasing efficiency for lab operations, especially in large-scale cell culture environments.
Services
1. Contract Research Services (CRO):
- MaxCyte offers contract research services to clients, providing expertise in cell engineering and development. This includes feasibility studies, process development, and optimization.
2. Consultative Services:
- The company provides consultative support for clients looking to implement cell-based therapies, offering guidance on best practices and optimization strategies for cell transfection and culture.
3. Custom Transfection Services:
- Tailored transfection services are available for clients who require specific cell types or complex transfection protocols, ensuring high efficiency and yield.
4. Training and Support:
- MaxCyte offers comprehensive training programs for researchers and clients to effectively use their systems and products, alongside ongoing technical support to resolve any operational challenges.
5. Regulatory Support:
- The company assists clients in navigating the regulatory landscape related to cell therapy and biomanufacturing, helping to prepare necessary documentation and compliance protocols.
Collaborations and Partnerships
MaxCyte has established several strategic partnerships with major biotech and pharmaceutical companies, as well as academic institutions. These collaborations enhance the companys offerings and allow for shared innovation in the fields of cell and gene therapy development.
Conclusion
MaxCyte Inc. plays a pivotal role in advancing cell-based therapies and drug development through its innovative technologies and comprehensive service offerings. By providing a broad array of products designed for cell engineering, MaxCyte facilitates cutting-edge research and the development of new therapeutics that hold the potential for significant medical breakthroughs. The company’s commitment to supporting the needs of researchers and developers in the biotechnology sector positions it as a valuable partner in the evolving landscape of cell and gene therapies.
Segments
1. Cell Therapy:
- MaxCyte is actively involved in the cell therapy space, focusing on providing tools that enable the engineering of cells for therapeutic purposes. This includes applications for cancer treatments and regenerative medicine.
2. Gene Therapy:
- The company develops technology that supports the delivery of genetic material into cells. This is pivotal for the development of gene therapies aimed at addressing genetic disorders and diseases.
3. Biomanufacturing:
- MaxCyte provides solutions for the scalable production of cells and biologics, making it an essential partner for companies engaged in the manufacturing of cell-based products.
Products
1. MaxCyte® GT Devices:
- These are scalable, automated systems designed for the transfection (delivery of nucleic acids into cells) of a wide variety of cell types, including stem cells and primary cells. They are instrumental in research and product development stages.
2. Large-Scale Transfection Systems:
- MaxCyte offers advanced transfection systems capable of handling significant volumes, making them suitable for commercial production of cell therapies and vaccines.
3. MaxCyte® ExPERT™ System:
- A key product for high-performance transfection, the ExPERT system is utilized for various applications, including CRISPR gene editing, antibody production, and CAR-T cell therapies.
4. Cell Line Development:
- The company provides tools and protocols for developing stable cell lines that are essential for producing biologics, offering a customization service according to client needs.
5. Product Automation Solutions:
- MaxCyte integrates automation into its offerings, enabling high-throughput processing and increasing efficiency for lab operations, especially in large-scale cell culture environments.
Services
1. Contract Research Services (CRO):
- MaxCyte offers contract research services to clients, providing expertise in cell engineering and development. This includes feasibility studies, process development, and optimization.
2. Consultative Services:
- The company provides consultative support for clients looking to implement cell-based therapies, offering guidance on best practices and optimization strategies for cell transfection and culture.
3. Custom Transfection Services:
- Tailored transfection services are available for clients who require specific cell types or complex transfection protocols, ensuring high efficiency and yield.
4. Training and Support:
- MaxCyte offers comprehensive training programs for researchers and clients to effectively use their systems and products, alongside ongoing technical support to resolve any operational challenges.
5. Regulatory Support:
- The company assists clients in navigating the regulatory landscape related to cell therapy and biomanufacturing, helping to prepare necessary documentation and compliance protocols.
Collaborations and Partnerships
MaxCyte has established several strategic partnerships with major biotech and pharmaceutical companies, as well as academic institutions. These collaborations enhance the companys offerings and allow for shared innovation in the fields of cell and gene therapy development.
Conclusion
MaxCyte Inc. plays a pivotal role in advancing cell-based therapies and drug development through its innovative technologies and comprehensive service offerings. By providing a broad array of products designed for cell engineering, MaxCyte facilitates cutting-edge research and the development of new therapeutics that hold the potential for significant medical breakthroughs. The company’s commitment to supporting the needs of researchers and developers in the biotechnology sector positions it as a valuable partner in the evolving landscape of cell and gene therapies.